A specific antibody for 2,3-dihydro-2,3-dihydroxyaflatoxin B1 (AFB1-diol) was prepared, and its reactivity was characterized for the major aflatoxin (AF) B1 (AFB1) metabolites. Reductive alkylation was used to conjugate AFB,-diol to ethylenediamine-modified bovine serum albumin (EDA-BSA) and horseradish peroxidase for use as an immunogen and an enzyme-linked immunosorbent assay (ELISA) marker, respectively. High reactant ratios, 1:5 and 1:10, for AFB1-diol-EDA-BSA (wt/wt) resulted in precipitated conjugates which were poorly immunogenic. However, a soluble conjugate obtained by using a 1:25 ratio of AFB1-diol to EDA-BSA could be used for obtaining high-titer AFBI-diol rabbit antibody within 10 weeks. Competitive ELISAs revealed that the AFB,-diol antibody detected as little as 1 pmol of AFB1-diol per assay. Cross-reactivity of AFB1-diol antibody in the competitive ELISA with AF analogs was as follows: AFB1-diol, 100%; AFB1, 200%; AFM1, 130%; AFB2a, 100%; AFGI, 6%; AFG2, 4%; aflatoxicol, 20%; AFQ1, 2%; AFB1-modified DNA, 32%; and 2,3-dihydro-2-(N7-guanyl)-3-hydroxy AFB1, 0.6%. These data indicated that the cyclopentanone and methoxy moieties of the AF molecule were the primary epitopes for the AFB1-diol antibody. The AFB1-diol competitive ELISA was subject to substantial interference by human, rat, and mouse serum albumins but not by BSA, Tris, human immunoglobulin G, or lysozyme. By using a noncompetitive, indirect ELISA with an AFB1-modified DNA solid phase, a modification level of one AFB1 residue for 200,000 nucleotides could be determined.
Aflatoxin (AF) B1 (AFB1) is a potent mycotoxin produced
by certain strains of Aspergillus flavus and A. parasiticus that has been shown to occur naturally in human foods and animal feeds (5) . Epidemiological studies in East Africa (25) , the Phillipines (4), and Thailand (37) suggest a relationship between dietary AF intake and human liver cancer. AFB, and other AFs are also extremely hepatotoxic and have been implicated in a number of human and livestock toxicoses (31, 36) .
The carcinogenic and acute toxic effects of AFB, have been related to two highly reactive metabolites formed by hepatic microsomal enzymes. Metabolic activation of AFB1 by a cytochrome P450 to a reactive epoxide at position 2, 3 of the terminal furan and subsequent covalent binding to nucleic acids have been suggested as key events in the carcinogenic process (21, 38) . The primary DNA adduct formed in vitro and in vivo is 2,3-dihydro-2-(N7-guanyl)-3-hydroxy AFB1 (AFB,-N7-Gua) (8, 19, 20) . Because of a localized positive charge, the imidazole ring of AFBI-N7-Gua can open under physiological conditions to yield a more stable, persistent adduct, the putative 2,3-dihydro-2-(N5-formyl-2',5',6'-triamino-4-oxo-N5-pyrimidyl)-3-hydroxy AFB, (AFB -FaPyr) (13, 19) . Although covalent binding of the 2, 3 epoxide to nucleophilic proteins is also likely, these adducts have not been characterized. A second major reactive metabolite, 2,3-dihydro-2,3-dihydroxy AFB1 (AFBI-diol) is formed in vitro after spontaneous or enzymatic reaction of the 2,3 epoxide with water (18, 22, 23) and as a degradation product of AFB1-N7-Gua-modified DNA (40) . At physiological and alkaline pH, AFB1-diol exists in a dialdehydic phenolate form and reacts with primary amino groups of proteins to form Schiff base adducts (22 rabbit reticulocyte systems and that relative rates of conversion of AFB1 to AFB1-diol in microsomal preparations from various species parallel the rank order of acute in vivo hepatotoxic effects in these animals. On this basis, it was suggested that the protein-binding ability of AFB1-diol is an important contributory factor in aflatoxicosis. However, at this time there is no conclusive evidence that AFBI-diol is similarly formed in vivo.
The ability to detect AFBI-diol and related metabolites is therefore of fundamental importance to understanding the molecular mode of action of AFB1. Extracts and hydrolysates containing AFB, metabolites are typically analyzed by high-pressure chromatography or by use of radioisotopes. AFB1-diol presents a special problem because it binds to protein and therefore cannot be extracted. To overcome this, in vitro studies include Tris buffer, which contains primary amino groups that trap AFB1-diol immediately on formation. This allows easy extraction and quantitation of the AFB1-diol-Tris adduct by high-pressure liquid chromatography (22, 23) . Recently we reported the efficacy of using specific antiserum prepared against 2,3-dihydro-2-hydroxy AFB1 (AFB2a) for the enzyme-linked immunosorbent detection of AFB1, AFB2a, AFB1-diol, AFBI-modified DNA, AFB1-N7-Gua, and AFB1-FaPyr (27) . Production of the antiserum was based on the ability of AFB2a, like AFB,-diol, to react with primary amines at neutral and alkaline pH (1) . A reductive alkylation method was thus used for conjugating the toxin to a bovine serum albumin (BSA) carrier protein for preparation of an immunogen. Resultant antibodies prepared against AFB2a-BSA had greatest specificity for the cyclopentanone and methoxy groups of the parent AF molecule (9, 28) . AFB2a antibody has also been used in the indirect immunoperoxidase localization of bound AFB1 in rat liver (26) .
Since AFB1-diol is hydroxylated at the 2,3 position and AFB2a is hydroxylated only at the 2 position, we hypothesized that antiserum prepared against AFBI-diol conjugates AFB1-N'-Gua DNA was prepared by the microsomal incubation procedure of Lin et al. (19) as modified by Pestka et al. (27) .
Preparation of immunogen and enzyme markers. For the protein carrier used in the immunogen, ethylenediamine (EDA) was conjugated to fatty acid-free BSA with watersoluble carbodiimide by the method of Chu et al. (7). AFB1-diol was then conjugated to EDA-BSA by a modification of the reductive alkylation method previously used for AFB2a (9) . Briefly, 0.05 to 1.0 ml of AFB1-diol in water (0.25 mg/ml) was added to 2 ml of EDA-BSA (2.5 mg/ml) in 0.05 M phosphate buffer (pH 7.2). The solution was gently swirled and allowed to stand for 30 min at 37°C. During this period the reaction mixture turned bright yellow. A 50-,lI volume of sodium borohydride solution (0.013 M) was added per ml of original reaction mixture and gently mixed, and the mixture was held for an additional 30 min at 25°C. A 25-,u volume of 0.1 N HCl per ml of reaction mixture was added to destroy residual NaBH4, and this mixture was dialyzed against 3 liters of 0.05 M phosphate buffer (pH 7.2) for 2 days (three changes) at 4°C. AFBI-diol concentrations and ratios of AFBI-diol-EDA-BSA conjugates were determined from the molar absorbance of AFB1 (e of 21,800 at 362 nm) (39) . For the AFB,-diol-horseradish peroxidase ELISA marker, reductive alkylation was performed exactly as described for EDA-BSA, with a 1:50 (wt/wt) toxin-enzyme ratio.
Immunization. Rabbits were immunized at multiple sites with 500 ,ug of immunogen (3 ml) mixed with saline-Freund complete adjuvant (1:2). Boosters of 500 ,ug of immunogen (1.5 ml) mixed with saline-Freund incomplete adjuvant (1:2) were injected intramuscularly at weeks 8 and 16. Rabbits were bled via marginal veins, and IgG was purified by the method of Herbert et al. (12) . Titers were determined by ELISA as described by Pestka et al. (27) .
Competitive ELISA. The procedure for the microtiter plate competitive ELISA was identical to that described for AFB2a (28) except that AFB1-diol antibody and AFB,-diolperoxidase were used as described above for solid-phase immunosorbent and enzyme marker, respectively. The wells were washed five times, and then the mixture was reacted with 50 p.l of goat anti-rabbit peroxidase conjugate (Miles Laboratories, Inc., Elkhart, Ind.), diluted 1:1,000 in PBS-BSA, for 30 min at 37°C. The plates were washed five more times, and the level of bound enzyme was determined as described by Pestka et al. (27) . Absorbance at 414 nm was measured on a Dynatech Microelisa Minireader. RESULTS
Immunogen preparation. Since AFB1-diol is a low-molecular-weight compound, it must be conjugated to a carrier protein to be rendered immunogenic. To facilitate this, EDA was first conjugated to free carboxyl groups of BSA to increase the number of available amino groups for subsequent mycotoxin conjugation (7) . For conjugation of AFBrdiol to EDA-BSA, the two reactants were mixed in various ratios at pH 7.5 to form Schiff base adducts. Conjugates were stabilized by reduction with NaBH4. High ratios of mycotoxin to carrier protein, 1:5 (conjugate A) and 1:10 (conjugate B), resulted in precipitated conjugates during the first 30 min of reaction. (Absorbance at 362 nm could not be determined.). This was probably due to denaturation of the EDA-BSA after reaction with AFB1-diol. The lower reactant ratios, 1:25 (conjugate C), 1:50 (conjugate D), and 1:100
(conjugate E), yielded soluble conjugates with AFB1-diol-EDA-BSA molar ratios of 7.4, 6.2, and 3.3, respectively. These final conjugate molar ratios are typical of those achieved previously for other mycotoxins (7) . The final reaction volumes of conjugates A, B, C, D, and E were 6, 4, 2.8, 2.4, and 2.2 ml, respectively. Antibody production. To compare the relative immunogenicity of insoluble and soluble conjugates, we used conjugates A and C for antibody production in rabbits. Conjugate A, the insoluble immunogen prepared with a high toxin-tocarrier reactant ratio, failed to yield a significant antibody titer in either rabbit J-9 or J-10, reaching only 250 after 18 weeks (Table 1) . However, conjugate C, the soluble immunogen with a final toxin-to-carrier molar ratio of 7.4, gave high titers, 3,240 and 9,720 for rabbits J-11 and J-12, respectively, after only 10 weeks. These results suggest that the toxin-carrier protein conjugates must be soluble for adequate antibody production. J-12 antiserum was used for all subsequent ELISA studies.
Competitive ELISA and specificity. A competitive ELISA was used to test the suitability of the AFB1-diol antibody for detection of AFB,-diol and related analogs (Fig. 1) (Fig. 2) . When 50 ng of AFB1-modified DNA was used to coat the microplate wells, AFBl-diol antibody could be diluted 1:51,200 and still yield a signal-to-noise ratio (modified-unmodified) of 12. The effect of increasing the number of nucleotides relative to the number of AFB1 residues in the AFB1-diol noncompetitive ELISA for AFB1-modified DNA was determined (Fig. 3) . The minimum detection limit for AFB1-modified DNA was arbitrarily defined as that level giving a signal-to-noise ratio of 2 
DISCUSSION
Specific antibodies against AFs and other carcinogens are extremely useful as immunological probes of the molecular mode of action of these compounds and as analytical tools for quantitating them in the environment. Several approaches for obtaining specific antibodies for AFB1 and its analogs have already been described by workers in our laboratory and by others (6, 9-11, 14, 16, 17, 29) . We report here for the first time the conditions for preparing and characterizing AFB,-diol antisera, as well as the procedures for its use in AFIB1 metabolism studies. In regard to antibody preparation, useful antiserum could be obtained in only 10 weeks. A soluble AFB,-diol-EDA-BSA conjugate was essential for production of this high-titer antiserum. In general, insoluble conjugates are poor immunogens because insolubility renders themn inaccessible to the immunological system. In addition, the AFB1-diol molecule may also be masked because of the denaturation of the protein, making the toxin unavailable for immune stimulus. Although this might be generalized for other mycotoxin-carrier conjugates, it has been reported that T-2 toxin antibody can be more readily obtairied by immunization with insoluble toxin-protein conjugates rather than soluble ones (30) .
The AFB,-diol immunogen and the previously described AFB2a imniunogen are similar in that the cyclopentanone ring and the methoxy group of the AF molecule acts as the primary epitope. The only difference between the two immunogens was the presence of a hydroxyl group at position 3 in AFB,-diol. Although it is likely that this hydroxyl group was located very close to the protein carrier and was not immunodominant, some differences in the relative specificities of the two antibodies were apparent. Table 2 compares the specifity data obtained for AFB1-diol antibody with those for AFB2a antibody (9, 27) . The AFB1-diol antiserum appeared to have a broader range of specificity for AFB, analogs, especially aflatoxicol and AFM1, than did AFB2a antiserum. Whereas AFB, and AFM, were more effective than AFB,-diol and AFB2a in competing in the AFB1-diol ELISA, lower reactivities for AFB, and AFM, compared with those for AFB2a and AFB,-diol were found in the AFB2a ELISA. In general, the AFB1-diol antiserum required higher concentrations of AFB1-diol, AFB2a, AFB1-modified DNA, and AFB,-N7-Gua than did AFB2a antiserum to inhibit their respective peroxidase conjugates. This suggests that AFB2a antibody has higher affinity for these key metabolites than does AFB1-diol antibody. Although differences in specificity and affinity between these two antibodies may be related to the presence of an additional hydroxyl group on the AF molecule in the AFB1-diol-EDA-BSA immunogen, they may also be related to the presence of the EDA bridge. Further studies comparing the efficacy of EDA-BSA and BSA as carriers for AFB1-diol and AFB2a antiserum are therefore warranted. Also, since rabbit antisera vary between animals and with bleeding times, specific monoclonal antisera against AFB2a and AFB1-diol should be prepared for more thorough comparisons.
It It is also significant that rabbit antisera prepared against AFB1-diol conjugate, as well as those prepared previously for AFB1 carboxymethyloxime (7, 16 ), AFM1 carboxymethyloxime (28) , AFB2a hemiglutarate (17) , and AFB2a (9, 29) , showed cross-reactivity with AFB1 analogs which were dependent on the mechanism of conjugation to the protein carrier but that monoclonal antisera prepared against AFB1-N7-Gua-modified DNA (10, 11) and AFB1 FaPyr-modified DNA (14) showed virtually no cross-reactivity with related analogs, such as AFB1-dibl, AFB2a, and AFB1-N7-Gua. Although this may be attributable to the high specificity of hybridoma antibodies, the latter two antibodies may have a high degree of recognition for alterations in the intact DNA molecule resulting from AFB1 modification rather than from the actual AF molecule. This possibility is supported by the fact that AFB1-FaPyr-modified DNA antibody is very reactive for both AFB1-modified IINA and AFG,-modified DNA (14) . Since both AFB1 and AFG1 are bound to the guanine residue at C-2 of the AF molecule, the respective cyclopentanone and tetrahydropyranone rings should be most exposed. The fact that AFB1-FaPyr-modified DNA antibody cross-reacts with both these forms of modified DNA suggests that the primary epitope in the generation of this antibody was not the AFB1 molectule but rather some alteration in the modified DNA molectlle that is not present in unmodified DNA. In contrast, the cross-reactivity of AFB1-diol and AFB2a antisera with AFB1-modified DNA and closely related analogs suggests that part of the AF molecule was the primary epitope in their. generation. When a noncompetitive ELISA with an AFB1-modified DNA solid-phase immunosorbent was used, AFB, bound covalently to calf thymus DNA at a modification level of one AFB1 molecule per 200,000 nucleotides. Since this modification level has been shown to occur in experimental animals in vivo after exposure to AFB1, the noncompetitive ELISA might be using AFB1-diol antibody and might be sufficiently sensitive for monitoring covalent AFB, binding in vivo. The sensitivity of the assay is comparable to that described for assays with monoclonal antibodies prepared against AFB1-FaPyr-modified DNA (one AFBi per 300,000 nucleotides [14] ), but is lower than that of assays with monoclonal antibodies derived against AFB1-N7-Gua-modified DNA (one AFBI per 1,355,000 nucleotides [10] ). The latter study employed ultrasensitive enzyme radioimmunoassay to attain high sensitivity. Thus, detection limits for AFBI-modified DNA detection with AFB1-diol antibody might be similarly enhanced by using hybridoma technology and the ultrasensitive assay.
High-performance liquid chromatography and radioisotopic methods are not completely adequate for monitoring AFB1 metabolism in vitro and in vivo. Specific antibodies against AFB, metabolites are useful alternatives to these approaches and might be used to discern the intracellular fate of AFB, in the liver and other organs at the ultrastructural level. We previously described the use of AFB2a antiserum in the immunoperoxidase light-microscopic localization of AFB, in livers of rats experimentally dosed with this carcinogen (26) . This study describes a simple procedure for the generation of AFB,-diol antiserum, the specificity of which was consistent with the proposed Schiff base mechanismn of AFB1-diol binding to primary amino groups. Thus, depending on the desired specificity, AFB1-diol, as well as AFB2a, antiserum can be used as a diagnostic tool for the detection of aflatoxicosis in humans and animals or as an immunological probe of AFB1 macromolecule interactions.
